Adicet Q3: $100.9M Cash Into 2H 2027, Pivotal Lupus Study Starting, FDA Meeting in 4Q
ACET is trading near its 52-week low of $2.87 (2.8% above the low) on elevated volume (2.0× avg).
Summary
Adicet reported a narrower Q3 loss ($18.9M vs $26.9M) and $100.9M in cash it says funds operations into 2H 2027, while starting a pivotal lupus nephritis study and planning a 4Q 2026 FDA meeting on expanding it to non-renal lupus.
Key Events · Earnings and Guidance · ACET
-
Q3 Loss Narrows on Lower Spend
Net loss was $18.9M, or $1.76 per basic and diluted share, versus $26.9M ($4.72 per share) in Q3 2025; R&D fell to $15.6M from $22.9M and G&A to $4.2M from $5.1M.
-
Cash Runway Into Second Half 2027
Cash, cash equivalents and short-term investments totaled $100.9M at September 30, 2026, down from $158.5M at December 31, 2025; the company expects funding into 2H 2027.
-
Pivotal Lupus Nephritis Study Starting
Start-up activities are underway for a single-arm pivotal study in lupus nephritis, with complete renal response at 12 months as the primary endpoint and a double-digit patient target.
-
FDA Meeting Set for Fourth Quarter
The company plans 4Q/2026 FDA engagement on expanding the pivotal program to lupus patients without nephritis, with a regulatory update and 12-month data from ~22 patients expected in 1Q/2027.
Analysis · ACET · Life Sciences
The quarter itself is a cost story: R&D fell to $15.6M from $22.9M and G&A to $4.2M from $5.1M, cutting the net loss to $18.9M from $26.9M a year ago. More important is what the cash buys — $100.9M funds operations into the second half of 2027, past the 1Q/2027 regulatory update and 12-month prula-cel follow-up and the 2Q/2027 systemic sclerosis readout. The company has begun start-up on a single-arm pivotal lupus nephritis study and will meet the FDA in 4Q/2026 about extending that pivotal program to lupus patients without nephritis, a materially larger label if granted. With the stock near its 52-week low, the risk is that the pivotal study and the in vivo CAR-T buildout consume the runway before a partnering or financing decision is forced.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACET was trading at $2.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.3M. The 52-week trading range was $2.87 to $11.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.